Zhaoke Ophthalmology’s CsA Ophthalmic Gel NDA Accepted by NMPA

An update from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.

Zhaoke Ophthalmology Limited announced that the National Medical Products Administration of China has accepted its New Drug Application for the CsA Ophthalmic Gel, a treatment for moderate to severe dry eye disease. The gel, which is a proprietary hydrogel formulation, offers improved pharmacokinetic profiles and patient compliance due to its once-daily application and rapid onset of action. This acceptance marks a significant step for the company in enhancing its market position in the ophthalmic industry.

More about Zhaoke Ophthalmology Ltd.

Zhaoke Ophthalmology Limited is a company incorporated in the British Virgin Islands and continued in the Cayman Islands, focusing on the development of innovative ophthalmic products. The company specializes in treatments for eye diseases, with a particular emphasis on products like the CsA Ophthalmic Gel, which targets moderate to severe dry eye disease.

Average Trading Volume: 2,590,007

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.18B

For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.